ABSTRACT
BACKGROUND AND PURPOSE: All the types of the glial cells contain estrogen (ER) and progesterone receptors (PR) but their occurrence in glial tumors of the brain is still controversial. The aim of this research was the clinical analysis of ER and PR expression in correlation with histological malignancy and expression of p53 and PCNA. MATERIAL AND METHODS: The investigation was carried out on a group of 56 patients operated on at the Neurosurgical Department of Wroclaw Medical University. The percentage of tumors containing ER and PR was assessed and mean receptor expressions were compared. Classical histological tests, immunohistochemical tests for ER, PR, p53 and PCNA with monoclonal antibodies (DACO) were performed for every specimen of tumor tissue. RESULTS: ER occurred in 24 cases (42.9%), PR in 10 cases (17.9%). 49% of highly malignant gliomas (WHO III and IV) were ER positive, whereas 29% of tumors grade I and II were ER positive. Frequencies of PR positive tumors were similar in both groups. Mean PR expression in p53 positive group was 8% and in p53 negative group 1.5% (p=0.017). Mean ER expression in PCNA positive group was 7.4%, whereas in PCNA negative group 2.7% (p<0.01). CONCLUSIONS: Frequency of ER occurrence is higher in highly malignant tumors. ER expression is correlated with proliferative activity (PCNA). PR expression is positively correlated with intensity of mutant p53 protein.
Subject(s)
Brain Neoplasms/metabolism , Glioma/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Receptors, Estradiol/metabolism , Receptors, Progesterone/metabolism , Tumor Suppressor Protein p53/genetics , Adult , Aged , Antibodies, Monoclonal/immunology , Brain Neoplasms/immunology , Female , Glioma/immunology , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Staging , Proliferating Cell Nuclear Antigen/immunology , Receptors, Estradiol/immunology , Receptors, Progesterone/immunology , Tumor Suppressor Protein p53/immunologyABSTRACT
BACKGROUND AND PURPOSE: The aim of this study was to evaluate clinical usefulness of proliferating cell nuclear antigen (PCNA), Ki67 antigen, p53 protein and silver-binding nucleolar organizer regions (AgNOR) in brain glial tumors. MATERIAL AND METHODS: The investigation of PCNA, Ki67 and p53 was carried out on a group of 120 patients with glial tumors operated on at the Neurosurgical Department of Wroclaw Medical University including 63 patients operated again because of recurrence. AgNOR was evaluated on a group of 64 patients including 38 patients operated again. Classical histological tests, immunohistochemical tests for PCNA, p53 and Ki67 activity with monoclonal antibodies (DACO) and histochemical tests for AgNOR were performed on every specimen of tumor tissue. The level of 40% for PCNA, 2.75 (equal to median) for AgNOR and 5% for Ki67 and p53 was adopted as significant. RESULTS: Mean expression of PCNA of glial tumors grade I and II was 32%, grade III and IV - 44% (p<0.05). Mean expression of AgNOR was 1.88 and 3.16 (p=0.00001), respectively. Average PCNA expression in recurrent tumors to 12 months was 52.7% and for later recurrences - 35.4% (p<0.05). Average expressions of AgNOR were 3.38 and 2.68 (p<0.05), respectively. Differences of Ki67 and p53 expressions were not significant. CONCLUSIONS: PCNA and AgNOR expressions correlate with proliferative activity, growth rate and histological malignancy, reaching high values in highly malignant and early recurrent tumors. Antigens Ki67 and p53 do not seem to be predictive markers of glial tumors.
